Status: Recruiting
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or metastatic solid tumors (including but not limited to head and neck cancer, malignant melanoma, CRC, renal cell carcinoma, cervical cancer, and breast cancer). Study details include:
Participants needed: 125
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: GeneMedicine Co., Ltd.Updated: Mar 21, 2024Locations: 4
Eligibility criteria
Patient must be 18 years of age or over, at the time of signing the informed con... [+13]
Known history or eiciency virus [HIV]/acquired immunodeficiency syndrome [AIDS])... [+17]